Journal
JOURNAL OF NEUROIMMUNE PHARMACOLOGY
Volume 10, Issue 4, Pages 645-650Publisher
SPRINGER
DOI: 10.1007/s11481-015-9639-4
Keywords
Alzheimer's disease; Parkinson's disease; Amyotrophic lateral sclerosis; Stroke; Adaptive immunity; Regulatory T cells; Effector T cells; Innate immunity; Neuroprotection; Neurodestruction; Neurodegenerative diseases
Categories
Funding
- University of Nebraska Foundation
- Department of Defense [W81XWH11-1-0700]
- National Institutes of Health [R01 NS070190, P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P01 NS43985, P30 MH062261, R01 AG043540]
Ask authors/readers for more resources
Aberrant innate and adaptive immune responses are neurodegenerative disease effectors. Disease is heralded by a generalized, but subtle immune activation orchestrated by the release of extracellular prion-like aggregated and oxidized or otherwise modified proteins. These are responsible for an inflammatory neurotoxic cascade. The perpetrators of such events include effector T cells and activated microglia. What ensues are Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis and stroke with changed frequencies of effector T cell and reduced numbers or function of regulatory lymphocytes. The control of such immune responses could lead to new therapeutic strategies and the means to effectively combat a composite of diseases that have quite limited therapeutic options.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available